Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

被引：28

作者：

Ellingsen, Espen Basmo ^{[1
,2
,3
]}

Mangsbo, Sara M. ^{[4
,5
]}

Hovig, Eivind ^{[1
,6
]}

Gaudernack, Gustav ^{[3
]}

机构：

[1] Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway

[2] Univ Oslo, Fac Med, Oslo, Norway

[3] Ultimovacs ASA, Res & Dev, Oslo, Norway

[4] Ultimovacs AB, Res & Dev, Uppsala, Sweden

[5] Uppsala Univ, Sci Life Lab, Dept Pharmaceut Biosci, Uppsala, Sweden

[6] Univ Oslo, Ctr Bioinformat, Dept Informat, Oslo, Norway

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

cancer; telomerase; immunotherapy; cancer vaccine; hTERT; melanoma; immune response; immuno-oncology; TERT PROMOTER MUTATIONS; CD4(+) T-CELLS; PHASE-II TRIAL; PEPTIDE VACCINATION; PANCREATIC-CANCER; LUNG-CANCER; GM-CSF; CHECKPOINT BLOCKADE; PROGNOSTIC IMPACT; IMMUNE PRIVILEGE;

D O I：

10.3389/fimmu.2021.682492

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy of checkpoint inhibition. Telomerase stands as an attractive target for TCVs due to its almost universal presence in cancer and its essential function promoting tumor growth. Herein, we review tumor telomerase biology that may affect the efficacy of therapeutic vaccination and provide insights on optimal vaccine design and treatment combinations. Tumor types possessing mechanisms of increased telomerase expression combined with an immune permissive tumor microenvironment are expected to increase the therapeutic potential of telomerase-targeting cancer vaccines. Regardless, rational treatment combinations, such as checkpoint inhibitors, are likely necessary to bring out the true clinical potential of TCVs.

引用

页数：15

共 146 条

[1] Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells [J].

Baharom, Faezzah ;

Ramirez-Valdez, Ramiro A. ;

Tobin, Kennedy K. S. ;

Yamane, Hidehiro ;

Dutertre, Charles-Antoine ;

Khalilnezhad, Ahad ;

Reynoso, Glennys, V ;

Coble, Vincent L. ;

Lynn, Geoffrey M. ;

Mule, Matthew P. ;

Martins, Andrew J. ;

Finnigan, John P. ;

Zhang, Xiao Meng ;

Hamerman, Jessica A. ;

Bhardwaj, Nina ;

Tsang, John S. ;

Hickman, Heather D. ;

Ginhoux, Florent ;

Ishizuka, Andrew S. ;

Seder, Robert A. .

NATURE IMMUNOLOGY, 2021, 22 (01) :41-52

[2] Dysfunction of antigen processing and presentation by dendritic cells in cancer [J].

Bandola-Simon, Joanna ;

Roche, Paul A. .

MOLECULAR IMMUNOLOGY, 2019, 113 :31-37

[3] Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition [J].

Bechter, OE ;

Zou, Y ;

Walker, W ;

Wright, WE ;

Shay, JW .

CANCER RESEARCH, 2004, 64 (10) :3444-3451

[4] Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study [J].

Bernhardt, S. L. ;

Gjertsen, M. K. ;

Trachsel, S. ;

Moller, M. ;

Eriksen, J. A. ;

Meo, M. ;

Buanes, T. ;

Gaudernack, G. .

BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1474-1482

[5] Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer [J].

Bertorelle, R. ;

Briarava, M. ;

Rampazzo, E. ;

Biasini, L. ;

Agostini, M. ;

Maretto, I. ;

Lonardi, S. ;

Friso, M. L. ;

Mescoli, C. ;

Zagonel, V. ;

Nitti, D. ;

De Rossi, A. ;

Pucciarelli, S. .

BRITISH JOURNAL OF CANCER, 2013, 108 (02) :278-284

[6] Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy [J].

Bhattacharya, Palash ;

Budnick, Isadore ;

Singh, Medha ;

Thiruppathi, Muthusamy ;

Alharshawi, Khaled ;

Elshabrawy, Hatem ;

Holterman, Mark J. ;

Prabhakar, Bellur S. .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2015, 35 (08) :585-599

[7] Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide [J].

Bolonaki, Irini ;

Kotsakis, Athanassios ;

Papadimitraki, Elsa ;

Aggouraki, Despoina ;

Konsolakis, George ;

Vagia, Aphrodite ;

Christophylakis, Charalambos ;

Nikoloudi, Irini ;

Magganas, Elefterios ;

Galanis, Athanassios ;

Cordopatis, Paul ;

Kosmatopoulos, Kostas ;

Georgoulias, Vassilis ;

Mavroudis, Dimitris .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2727-2734

[8] Cold Tumors: A Therapeutic Challenge for Immunotherapy [J].

Bonaventura, Paola ;

Shekarian, Tala ;

Alcazer, Vincent ;

Valladeau-Guilemond, Jenny ;

Valsesia-Wittmann, Sandrine ;

Amigorena, Sebastian ;

Caux, Christophe ;

Depil, Stephane .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[9] CD4+ T cell help in cancer immunology and immunotherapy [J].

Borst, Jannie ;

Ahrends, Tomasz ;

Babala, Nikolina ;

Melief, Cornelis J. M. ;

Kastenmueller, Wolfgang .

NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) :635-647

[10] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

← 1 2 3 4 5 6 7 8 9 10 →